Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia.

Author: , BaumgartnerScott, FleischmannRoy, HingoraniVijay, KerrBradley, ManhardKimberly, MinerJeffrey N, PolventElizabeth, QuartBarry, ShenZancong, SusterMatt, YehLi-Tain

Paper Details 
Original Abstract of the Article :
OBJECTIVE: The aim of this study was to evaluate the pharmacodynamics (PDs), pharmacokinetics (PKs) and safety of lesinurad (selective uric acid reabsorption inhibitor) in combination with febuxostat (xanthine oxidase inhibitor) in patients with gout. METHODS: This study was a phase IB, multicentre...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1093/rheumatology/ket487

データ提供:米国国立医学図書館(NLM)

Combining Medications to Achieve Optimal Gout Treatment

Gout is a painful condition characterized by elevated uric acid levels in the blood, leading to inflammation and joint pain. This study investigates the efficacy and safety of combining lesinurad (a selective uric acid reabsorption inhibitor) with febuxostat (a xanthine oxidase inhibitor) to treat hyperuricemia in patients with gout.

The researchers conducted a phase IB, multicentre, open-label, multiple-dose study involving gout patients with elevated serum uric acid (sUA) levels. Patients received febuxostat monotherapy followed by the addition of lesinurad. sUA levels, urine uric acid excretion, and pharmacokinetic profiles were monitored throughout the study.

The results showed that the combination of lesinurad and febuxostat effectively reduced sUA levels to below the target range in all patients. Notably, no significant changes in the pharmacokinetic profiles of either drug were observed. The combination was well tolerated.

A Powerful Strategy for Gout Management

This study demonstrates the potential of combining lesinurad and febuxostat to achieve optimal uric acid control in gout patients. The combination therapy effectively reduces sUA levels and is well tolerated. This finding offers a promising strategy for managing gout and improving patient outcomes.

Managing Gout: A Holistic Approach

Gout management requires a multi-faceted approach that addresses both medication and lifestyle factors. This study highlights the potential benefits of combining medications to achieve effective uric acid control. However, it's essential to consult with a healthcare professional to develop an individualized treatment plan that considers your specific needs and medical history.

Dr. Camel's Conclusion

This study reminds us that, like the vast desert, gout requires a multi-faceted approach. Combining lesinurad and febuxostat provides a powerful strategy for managing uric acid levels, but it's essential to have a conversation with a healthcare professional to determine the best path for you. This research is an important step in the journey to finding a truly effective treatment for gout.

Date :
  1. Date Completed 2015-01-29
  2. Date Revised 2022-03-17
Further Info :

Pubmed ID

24509406

DOI: Digital Object Identifier

10.1093/rheumatology/ket487

Related Literature

Article Analysis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.